Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer
8.5
来源：
Nature
关键字：
ML brain science
发布时间：
2025-09-12 11:31
摘要：
This study explores the combined use of trametinib and anlotinib for treating KRAS-mutant non-small cell lung cancer (NSCLC). It highlights the high therapeutic efficacy of this combination, with a 69.2% objective response rate and a median progression-free survival of 6.9 months in a clinical trial involving advanced NSCLC patients. The research also addresses the mechanisms of adaptive resistance to MEK inhibitors, suggesting that targeting both MEK and receptor tyrosine kinases (RTKs) may enhance treatment outcomes. This innovative approach could represent a significant advancement in the management of KRAS-mutant NSCLC.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
The objective response rate (ORR) is 69.2% in the phase Ia trial.
The median progression-free survival (PFS) is 6.9 months.
The study provides a potential combinational therapeutic strategy for KRAS-mutant NSCLC.
真实性检查
否
AI评分总结
This study explores the combined use of trametinib and anlotinib for treating KRAS-mutant non-small cell lung cancer (NSCLC). It highlights the high therapeutic efficacy of this combination, with a 69.2% objective response rate and a median progression-free survival of 6.9 months in a clinical trial involving advanced NSCLC patients. The research also addresses the mechanisms of adaptive resistance to MEK inhibitors, suggesting that targeting both MEK and receptor tyrosine kinases (RTKs) may enhance treatment outcomes. This innovative approach could represent a significant advancement in the management of KRAS-mutant NSCLC.